In Big Pharma it takes over 12 years to bring a new drug to market and costs over $1billion. Promising leads are found to be toxic very late in the development cycle leading to inefficiency in drug development and overall R&D ROI of less than 5%. In the organic materials space, industrial chemical processes remain un-optimized and costly to improve.
Uniqueness, Technology overview, barriers to competition
The new science behind our software, its computational speed and its SaaS cloud-based implementation has the potential to make chemical modelling available to hundreds of thousands of non-expert chemists. We have freedom to operate and our proprietary IP is protected.
Market size and analysis
The chemical R&D market across pharma, materials and fine chemicals is $260 billion p.a., with 8% spent directly on computation. The proportional spend on computing tools is expected to double by 2020. Globally, over 800k chemical professionals would benefit from applying ChemAlive software in their daily work.
Ask, use of proceeds, milestones
Get in touch
You need to log in or register to contact this startup.